||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 452 active entries
30 West 86th St. - 1B
New York, NY, USA 10024-3600
United States of America, New York
Phone: (212) 769-3877
Fax: (212) 769-3877
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
- Therapeutic compositions to prevent desensitization or fade
- Pharmaceutical discovery and enhancement
- Molecular modeling
- Modeling of receptor-ligand interactions
- G protein coupled receptor (GPCR) models
Bio Balance (www.bio-balance.com) is an early stage drug development company that has developed the only tested method to prevent drug desensitization at the receptor level. This phenomenon, also known as down-regulation, tolerance or fade, occurs with a large number of very commonly used drugs such as dobutamine for heart failure, isoproterenol for shock or asthma, L-dopa for Parkinson's Disease, and morphine for pain. Notably, desensitization cannot be remedied by taking larger dosages. With more and more drug, efficacy diminishes and the drug essentially stops working. By using a patented approach, we create new, combination drug candidates that sustain the therapeutic response with a better side-effects profile than the original drugs.
Last update of this entry: February 13, 2020